Literature DB >> 36255615

Colony Formation Assay to Test the Impact of HDACi on Leukemic Cells.

Miriam Pons1, Mandy Beyer2.   

Abstract

One of the main characteristics of cancer is the rapid proliferation of transformed cells. Cancer therapies aim to kill such cells. Cancer clones surviving therapy can be resistant to the treatment, but they can also lose the ability to proliferate. The ability of single cells to proliferate can be monitored in vitro and can provide insights into the sensitivity of tumor cells to chemotherapeutics. The following chapter describes how clonogenic hematopoietic cell growth can be determined with the colony formation assay.
© 2023. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Colony formation; HDAC; Hematopoietic cells; Leukemia; Methyl cellulose; Proliferation; Survival

Mesh:

Year:  2023        PMID: 36255615     DOI: 10.1007/978-1-0716-2788-4_2

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  21 in total

Review 1.  Inhibitors of HDACs--effective drugs against cancer?

Authors:  S Müller; O H Krämer
Journal:  Curr Cancer Drug Targets       Date:  2010-03       Impact factor: 3.428

Review 2.  Epigenetic therapy of cancer with histone deacetylase inhibitors.

Authors:  K C Lakshmaiah; Linu A Jacob; S Aparna; D Lokanatha; Smitha C Saldanha
Journal:  J Cancer Res Ther       Date:  2014 Jul-Sep       Impact factor: 1.805

Review 3.  Drugging the HDAC6-HSP90 interplay in malignant cells.

Authors:  Oliver H Krämer; Siavosh Mahboobi; Andreas Sellmer
Journal:  Trends Pharmacol Sci       Date:  2014-09-16       Impact factor: 14.819

4.  Class I histone deacetylases regulate p53/NF-κB crosstalk in cancer cells.

Authors:  Claudia Schäfer; Anja Göder; Mandy Beyer; Nicole Kiweler; Nisintha Mahendrarajah; Anke Rauch; Teodora Nikolova; Natasa Stojanovic; Martin Wieczorek; Thomas R Reich; Maja T Tomicic; Michael Linnebacher; Jürgen Sonnemann; Sascha Dietrich; Andreas Sellmer; Siavosh Mahboobi; Thorsten Heinzel; Günter Schneider; Oliver H Krämer
Journal:  Cell Signal       Date:  2016-11-09       Impact factor: 4.315

5.  Histone deacetylase 1 (HDAC1), but not HDAC2, controls embryonic stem cell differentiation.

Authors:  Oliver M Dovey; Charles T Foster; Shaun M Cowley
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-19       Impact factor: 11.205

Review 6.  Interstrand Crosslink Repair as a Target for HDAC Inhibition.

Authors:  Teodora Nikolova; Nicole Kiweler; Oliver H Krämer
Journal:  Trends Pharmacol Sci       Date:  2017-07-04       Impact factor: 14.819

7.  The Role of HDACs as Leukemia Therapy Targets using HDI.

Authors:  Ahmad Ahmadzadeh; Elahe Khodadi; Mohammad Shahjahani; Jessika Bertacchini; Tina Vosoughi; Najmaldin Saki
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2015-10-01

8.  HDAC1 and HDAC2 integrate checkpoint kinase phosphorylation and cell fate through the phosphatase-2A subunit PR130.

Authors:  Anja Göder; Claudia Emmerich; Teodora Nikolova; Nicole Kiweler; Maria Schreiber; Toni Kühl; Diana Imhof; Markus Christmann; Thorsten Heinzel; Günter Schneider; Oliver H Krämer
Journal:  Nat Commun       Date:  2018-02-22       Impact factor: 14.919

Review 9.  Role of HDACs in normal and malignant hematopoiesis.

Authors:  Pan Wang; Zi Wang; Jing Liu
Journal:  Mol Cancer       Date:  2020-01-07       Impact factor: 27.401

10.  Histone deacetylase inhibitors dysregulate DNA repair proteins and antagonize metastasis-associated processes.

Authors:  Nicole Kiweler; Désirée Wünsch; Matthias Wirth; Nisintha Mahendrarajah; Günter Schneider; Roland H Stauber; Walburgis Brenner; Falk Butter; Oliver H Krämer
Journal:  J Cancer Res Clin Oncol       Date:  2020-01-13       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.